Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B Hanauer1, Brian G Feagan2, Gary R Lichtenstein3, Lloyd F Mayer4, S Schreiber5, Jean Frederic Colombel6, Daniel Rachmilewitz7, Douglas C Wolf8, Allan Olson9, Weihang Bao9, Paul Rutgeerts10
1Department of Gastroenterology and Nutrition, University of Chicago Medical Center, Chicago, IL, USA
2London Health Sciences Center, University of Western Ontario, London, Ontario, Canada
3Department of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
4Department of Clinical Immunology, Mount Sinai Medical Center, New York, NY, USA
5Klinikum der Christian-Albrechs-Universität, Kiel, Germany
6Hôpital Claude Huriez, CHU de Lille, Lille, France
7Division of Medicine, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel
8Atlanta Gastroenterology Associates, Atlanta, GA, USA
9Centocor, Malvern, PA, USA
10Afdeling Gastroenterologie, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
The Lancet
Tập 359
1541-1549
Thông tin tác giả